|
|
Post by akemp3000 on Jun 28, 2018 7:02:21 GMT -5
Wondering if anyone has told that hedge fund that their attempts to kill MNKD is not working  |
|
|
|
Post by barnstormer on Jun 28, 2018 7:05:23 GMT -5
Hedge funds rotate in and out of stocks constantly. They could easily dump their Novo and Lilly shares after increasing their MNKD holdings at bargain basement prices. Actually now would be a great time for them to start the rotation.
|
|
|
|
Post by peppy on Jun 28, 2018 8:30:15 GMT -5
Dr Kendall fun facts presented at investors conference.
I unit of RAA insulin = 34.7 mg of insulin, which is the amount of insulin it takes to reduce the blood glucose level of a 4.45 pound rabbit by 45 mg/dl.
|
|
|
|
Post by uvula on Jun 28, 2018 8:34:08 GMT -5
Dr Kendall fun facts presented at investors conference. I unit of RAA insulin = 34.7 mg of insulin, which is the amount of insulin it takes to reduce the blood glucose level of a 4.45 pound rabbit by 45 mg/dl. The big problem with rabbits is they keep chewing up the inhaler. |
|
|
|
Post by matt on Jun 28, 2018 9:06:15 GMT -5
Hedge funds rotate in and out of stocks constantly. They could easily dump their Novo and Lilly shares after increasing their MNKD holdings at bargain basement prices. Actually now would be a great time for them to start the rotation. More likely they would dump their MNKD for a short time, then reload. It is no secret the company has to raise money soon, that is why they had an investor conference, and when shares go out at a discount that usually drops the share price for everybody. Rather than jump into the stock most hedge funds will wait to go long, or short if they are not long, wait for the dust to settle from the financing, and then invest. The signs are all there for a near term financing event. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 28, 2018 9:09:23 GMT -5
Hedge funds rotate in and out of stocks constantly. They could easily dump their Novo and Lilly shares after increasing their MNKD holdings at bargain basement prices. Actually now would be a great time for them to start the rotation. More likely they would dump their MNKD for a short time, then reload. It is no secret the company has to raise money soon, that is why they had an investor conference, and when shares go out at a discount that usually drops the share price for everybody. Rather than jump into the stock most hedge funds will wait to go long, or short if they are not long, wait for the dust to settle from the financing, and then invest. The signs are all there for a near term financing event. So its trading at $1.88 now, fair to assume they want to raise a minimum of $30mm net? |
|
|
|
Post by boca1girl on Jun 28, 2018 9:13:47 GMT -5
If Castagna, Kendall, Edelman, and many others see this as game changing, and data supports it, why no partner or buyout? If it’s such a game changer, which I wholeheartedly agree, why such a struggle. Honest question. If they didn't believe it was game changing I do not think they could do their job (Dr Edelman aside since he is not an employee). The data has yet to be presented that solidly supports the case but hopefully Dr K is fixing that. Is Afrezza a nice to have or a game-changer, and what constitutes a game-changer? Look at Dr Edelman; he thinks Afrezza is great, but he only uses it for corrections and fast carbs, everything else is a pump with RAA. If it was truly a game-changer he would use Afrezza for everything other than basal insulin. I think it is a significant improvement, but I am not sure it's a game-changer. I also question why Dr. E just uses Afrezza on a limited basis. Why doesn’t he dump the pump? |
|
|
|
Post by sportsrancho on Jun 28, 2018 9:41:25 GMT -5
He uses it just for corrections although that’s a very good question, but Afrezza used for corrections in itself would be a big market.
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Jun 28, 2018 9:41:29 GMT -5
It's pretty hard to tell how much MNKD wants to raise based on the current sp.
But, I do not believe SP will be that badly affected by dilution. At least not for very long. The current SP has dilution somewhat baked-in already. With all the good news lately, it has remained stagnant at under $2. There are a lot of latent investors just champing at the bit waiting for dilution before they invest, so the SP will hopefully escalate quickly once dilution happens. I hope and believe that once dilution happens, it will never see $2 again.
I was guessing the raise to be between $20 and 50 million, and I was wishing for a larger number to get us into 2019 before we need another funding. However, with sp staying this low, I think I would rather see a smaller raise now, and another raise a little later after the sales improve and price appreciates some.
|
|
|
|
Post by agedhippie on Jun 28, 2018 9:43:25 GMT -5
Wondering if anyone has told that hedge fund that their attempts to kill MNKD is not working Hedge funds don't want MNKD to die, it has a role for them. If I was a hedge fund and building a model where I neeeded to nett out the influence of insulin sales or go over-weight insulin in a basket of diabetes drugs MNKD is the only option at the moment. It would make their life easier if the share price was higher because at the moment the share price is limiting the size of position they can buy (they don't want to take to much of the float or the model breaks because you are trading against yourself). |
|
|
|
Post by kite on Jun 28, 2018 9:48:54 GMT -5
In person recap:
* Yesterday’s investors conference was an intimate group of about 3 dozen people attending in person, with hundreds more listening online
* The management team did a great job with their presentations. The scientific presentations by Edelman and Kendall were very comprehensive. I was hoping Mike’s company overview presentation was more exciting
* Mike Castagna and David Kendall was present in person. This team has had a long week having just finished the ADA Conference this weekend. Edelman attended the ADA in person but participated digitally at yesterday’s investors conference
* After I picked up my name tag, Mike Castagna was right there to shake my hand and welcome me into the conference room. I was star struck
* There was no seating chart but I found myself sitting at a table with Ilya Kravets from HC. Wainwright, two people from MSQ Ventures (focused on partnering U.S. based technology, consumer, and healthcare companies with strategic Chinese corporate and institutional investors) and one person from Jeffries. There was really no time to chatter as the presentation started immediately
* FDA approved drugs have not moved the needle in taking care of diabetics for the past decade! There has been substantial advances but true innovation has been lacking. CGM + Afrezza will change that!
* Dr. Edelman believes the key to Afrezza being successful is adherence and persistence
* Kendall and Steve are friends. Kendall was a student of Steven Edelman
* Mike and Kendall are a one-two punch! The remainder of the year will be fun to watch as the team continues to present the results of past studies, both at upcoming national and international conferences
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 28, 2018 9:53:48 GMT -5
Thanks for the info Kite.
Regarding the question of disruption, Amazon just bought Pillpack.
|
|
|
|
Post by golfeveryday on Jun 28, 2018 9:54:51 GMT -5
In person recap: * Yesterday’s investors conference was an intimate group of about 3 dozen people attending in person, with hundreds more listening online * The management team did a great job with their presentations. The scientific presentations by Edelman and Kendall were very comprehensive. I was hoping Mike’s company overview presentation was more exciting * Mike Castagna and David Kendall was present in person. This team has had a long week having just finished the ADA Conference this weekend. Edelman attended the ADA in person but participated digitally at yesterday’s investors conference * After I picked up my name tag, Mike Castagna was right there to shake my hand and welcome me into the conference room. I was star struck * There was no seating chart but I found myself sitting at a table with Ilya Kravets from HC. Wainwright, two people from MSQ Ventures (focused on partnering U.S. based technology, consumer, and healthcare companies with strategic Chinese corporate and institutional investors) and one person from Jeffries. There was really no time to chatter as the presentation started immediately * FDA approved drugs have not moved the needle in taking care of diabetics for the past decade! There has been substantial advances but true innovation has been lacking. CGM + Afrezza will change that! * Dr. Edelman believes the key to Afrezza being successful is adherence and persistence * Kendall and Steve are friends. Kendall was a student of Steven Edelman * Mike and Kendall are a one-two punch! The remainder of the year will be fun to watch as the team continues to present the results of past studies, both at upcoming national and international conferences notice other companies there in addition to Jeffries? |
|
|
|
Post by MnkdWASmyRtrmntPlan on Jun 28, 2018 9:59:34 GMT -5
If they didn't believe it was game changing I do not think they could do their job (Dr Edelman aside since he is not an employee). The data has yet to be presented that solidly supports the case but hopefully Dr K is fixing that. Is Afrezza a nice to have or a game-changer, and what constitutes a game-changer? Look at Dr Edelman; he thinks Afrezza is great, but he only uses it for corrections and fast carbs, everything else is a pump with RAA. If it was truly a game-changer he would use Afrezza for everything other than basal insulin. I think it is a significant improvement, but I am not sure it's a game-changer. I also question why Dr. E just uses Afrezza on a limited basis. Why doesn’t he dump the pump? Sayhey has indicated that Dr. E is in an awkward position because he takes Afrezza himself, but he is a doctor that teaches patients to use a pump. Once you have a business built, it is hard to accept that it is built on sand. Even though Dr. E. knows the truth, it is unfortunately human nature that he will try to milk out his paychecks based on the highly-acclaimed experience and professional stature he has acquired as a pump advocate. My guess is that he will eventually change his tune. And, hey Sports, yet again you have a very good point. Pushing Afrezza even just for corrections would be a great stepping stone. The more PWDs use it, and the more good info that Dr. K drives to the market, and the more insurance improves, the more PWDs will start increasing their dosing until they get to the point where they decide to dump the pump. |
|
|
|
Post by kite on Jun 28, 2018 9:59:41 GMT -5
In person recap: * Yesterday’s investors conference was an intimate group of about 3 dozen people attending in person, with hundreds more listening online * The management team did a great job with their presentations. The scientific presentations by Edelman and Kendall were very comprehensive. I was hoping Mike’s company overview presentation was more exciting * Mike Castagna and David Kendall was present in person. This team has had a long week having just finished the ADA Conference this weekend. Edelman attended the ADA in person but participated digitally at yesterday’s investors conference * After I picked up my name tag, Mike Castagna was right there to shake my hand and welcome me into the conference room. I was star struck * There was no seating chart but I found myself sitting at a table with Ilya Kravets from HC. Wainwright, two people from MSQ Ventures (focused on partnering U.S. based technology, consumer, and healthcare companies with strategic Chinese corporate and institutional investors) and one person from Jeffries. There was really no time to chatter as the presentation started immediately * FDA approved drugs have not moved the needle in taking care of diabetics for the past decade! There has been substantial advances but true innovation has been lacking. CGM + Afrezza will change that! * Dr. Edelman believes the key to Afrezza being successful is adherence and persistence * Kendall and Steve are friends. Kendall was a student of Steven Edelman * Mike and Kendall are a one-two punch! The remainder of the year will be fun to watch as the team continues to present the results of past studies, both at upcoming national and international conferences notice other companies there in addition to Jeffries? HC. Wainwright and MSQ Ventures |
|
